Contact this trialFirst, we need to learn more about you.
Alkylating agent
Olaparib + Chemotherapy for Prostate Cancer
Recruiting3 awardsPhase 2
Houston, Texas
This trial is studying olaparib to see how well it works in combination with cabazitaxel, carboplatin, and prednisone in treating patients with aggressive variant prostate cancer.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.